271 related articles for article (PubMed ID: 38609727)
21. Treatment Options for Patients With Heavily Pretreated Relapsed and Refractory Multiple Myeloma.
Dimopoulos MA; Richardson P; Lonial S
Clin Lymphoma Myeloma Leuk; 2022 Jul; 22(7):460-473. PubMed ID: 35148975
[TBL] [Abstract][Full Text] [Related]
22. An evaluation of isatuximab, pomalidomide and dexamethasone for adult patients with relapsed and refractory multiple myeloma.
Piggin A; Prince HM
Expert Rev Hematol; 2021 May; 14(5):419-427. PubMed ID: 33945375
[TBL] [Abstract][Full Text] [Related]
23. Bispecific Monoclonal Antibodies in Multiple Myeloma: Data from ASH 2022: A Podcast.
Landgren O; Nadeem O
Adv Ther; 2023 Aug; 40(8):3291-3303. PubMed ID: 37328635
[TBL] [Abstract][Full Text] [Related]
24. Multiple Myeloma: The Role of Autologous Stem Cell Transplantation in the Era of Immunotherapy.
Rocchi S; Zannetti BA; Marconi G; Lanza F
Cells; 2024 May; 13(10):. PubMed ID: 38786075
[TBL] [Abstract][Full Text] [Related]
25. [Therapeutic approach for relapsed/refractory multiple myeloma: the logic and practice].
Kuroda J
Rinsho Ketsueki; 2017; 58(10):2058-2066. PubMed ID: 28978849
[TBL] [Abstract][Full Text] [Related]
26. Daratumumab in multiple myeloma: experience of the multiple myeloma GIMEMA Lazio group.
Vozella F; Siniscalchi A; Rizzo M; Za T; Antolino G; Coppetelli U; Piciocchi A; Andriani A; Annibali O; De Rosa L; Cimino G; La Verde G; De Stefano V; Cantonetti M; di Toritto TC; Petrucci MT
Ann Hematol; 2021 Apr; 100(4):1059-1063. PubMed ID: 33528611
[TBL] [Abstract][Full Text] [Related]
27. Management of Patients with Relapsed and/or Refractory Multiple Myeloma Treated with Novel Combination Therapies in Routine Clinical Practice in Germany.
Steinmetz HT; Singh M; Milce J; Haidar M; Rieth A; Lebioda A; Kohnke J
Adv Ther; 2022 Mar; 39(3):1247-1266. PubMed ID: 35034310
[TBL] [Abstract][Full Text] [Related]
28. Relapsed/Refractory Multiple Myeloma: A Review of Available Therapies and Clinical Scenarios Encountered in Myeloma Relapse.
Bhatt P; Kloock C; Comenzo R
Curr Oncol; 2023 Feb; 30(2):2322-2347. PubMed ID: 36826140
[TBL] [Abstract][Full Text] [Related]
29. Outcomes of Daratumumab, Pomalidomide, and Dexamethasone, Followed by High-dose Chemotherapy and Autologous Stem Cell Transplantation, in Patients With Relapsed/Refractory Multiple Myeloma.
Abdallah AO; Mohyuddin GR; Mahmoudjafari Z; Atrash S; Kawsar H; Sigle M; Shune L; McGuirk J; Ganguly S
Clin Lymphoma Myeloma Leuk; 2021 Feb; 21(2):e212-e219. PubMed ID: 33051166
[TBL] [Abstract][Full Text] [Related]
30. Chimeric Antigen Receptor T Cell Therapy for Myeloma: Where Are We Now and What Is Needed to Move Chimeric Antigen Receptor T Cells Forward to Earlier Lines of Therapy? Expert Panel Opinion from the American Society for Transplantation and Cellular Therapy.
Anderson LD; Dhakal B; Jain T; Oluwole OO; Shah GL; Sidana S; Perales MA; Pasquini MC
Transplant Cell Ther; 2024 Jan; 30(1):17-37. PubMed ID: 37913909
[TBL] [Abstract][Full Text] [Related]
31. Newly approved and forthcoming T-cell-redirecting bispecific antibodies for the treatment of relapsed/refractory multiple myeloma.
Granger K; Gaffney KJ; Davis JA
J Oncol Pharm Pract; 2023 Apr; 29(3):722-726. PubMed ID: 36775940
[TBL] [Abstract][Full Text] [Related]
32. Elranatamab vs. teclistamab: battle of the BCMA bispecifics in relapsed/refractory multiple myeloma.
Moore DC; Granger K; Hill H; Karabinos A; Davis JA
Expert Rev Hematol; 2024 Jun; 17(6):197-200. PubMed ID: 38717927
[No Abstract] [Full Text] [Related]
33. A safety review of recently approved and emerging drugs for patients with relapsed or refractory multiple myeloma.
Midha S; Hartley-Brown MA; Mo CC; Hossain S; Nadeem O; O'Donnell EK; Bianchi G; Sperling AS; Laubach JP; Richardson PG
Expert Opin Drug Saf; 2023; 22(11):1049-1071. PubMed ID: 37906232
[TBL] [Abstract][Full Text] [Related]
34. [The guidelines for the diagnosis and management of multiple myeloma in China(2020 revision)].
; ;
Zhonghua Nei Ke Za Zhi; 2020 May; 59(5):341-346. PubMed ID: 32370461
[TBL] [Abstract][Full Text] [Related]
35. [Mechanism of action and clinical results of immunotherapy for multiple myeloma].
Imai Y
Rinsho Ketsueki; 2022; 63(9):1180-1187. PubMed ID: 36198543
[TBL] [Abstract][Full Text] [Related]
36. Teclistamab, a B-cell maturation antigen × CD3 bispecific antibody, in patients with relapsed or refractory multiple myeloma (MajesTEC-1): a multicentre, open-label, single-arm, phase 1 study.
Usmani SZ; Garfall AL; van de Donk NWCJ; Nahi H; San-Miguel JF; Oriol A; Rosinol L; Chari A; Bhutani M; Karlin L; Benboubker L; Pei L; Verona R; Girgis S; Stephenson T; Elsayed Y; Infante J; Goldberg JD; Banerjee A; Mateos MV; Krishnan A
Lancet; 2021 Aug; 398(10301):665-674. PubMed ID: 34388396
[TBL] [Abstract][Full Text] [Related]
37. Immunotherapies Old and New: Hematopoietic Stem Cell Transplant, Chimeric Antigen Receptor T Cells, and Bispecific Antibodies for the Treatment of Relapsed/Refractory Diffuse Large B Cell Lymphoma.
Doraiswamy A; Shah MR; Bannerji R
Curr Hematol Malig Rep; 2021 Feb; 16(1):72-81. PubMed ID: 33619641
[TBL] [Abstract][Full Text] [Related]
38. Elotuzumab as a novel anti-myeloma immunotherapy.
Radhakrishnan SV; Bhardwaj N; Steinbach M; Weidner J; Luetkens T; Atanackovic D
Hum Vaccin Immunother; 2017 Aug; 13(8):1751-1757. PubMed ID: 28604269
[TBL] [Abstract][Full Text] [Related]
39. [Controversies on the diagnosis and treatment of relapsed/refractory multiple myeloma].
Chen WM; Lin ZY
Zhonghua Yi Xue Za Zhi; 2022 Aug; 102(30):2311-2314. PubMed ID: 35970789
[TBL] [Abstract][Full Text] [Related]
40. Isatuximab for the treatment of relapsed/refractory multiple myeloma.
Richardson PG; Beksaç M; Špička I; Mikhael J
Expert Opin Biol Ther; 2020 Dec; 20(12):1395-1404. PubMed ID: 33111607
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
